EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

October 16, 2024

Study Completion Date

December 27, 2024

Conditions
Chronic Rhinosinusitis With Nasal PolypsAsthma
Interventions
DRUG

Dupilumab

solution for injection subcutaneous

DRUG

Omalizumab

solution for injection subcutaneous

DRUG

Placebo

solution for injection subcutaneous

Trial Locations (87)

1083

Investigational Site Number : 3480007, Budapest

1115

Investigational Site Number : 3480004, Budapest

1200

Investigational Site Number : 0560003, Woluwe-Saint-Lambert

2100

Investigational Site Number : 2080001, Copenhagen

3000

Investigational Site Number : 0560002, Leuven

3780

Investigational Site Number : 3480006, Edelény

4026

Investigational Site Number : 3480005, Debrecen

6725

Investigational Site Number : 3480001, Szeged

7621

Investigational Site Number : 3480002, Pécs

8200

Investigational Site Number : 2080003, Aarhus

9000

Investigational Site Number : 0560001, Ghent

10034

Investigational Site Number : 2030010, Prague

11021

Northwell Health Site Number : 8400044, Great Neck

11407

Investigational Site Number : 7240003, Jerez de la Frontera

12808

Investigational Site Number : 2030006, Prague

13005

Investigational Site Number : 2500004, Marseille

13353

Investigational Site Number : 2760002, Berlin

14059

Investigational Site Number : 2030008, Prague

14642

University of Rochester Site Number : 8400015, Rochester

15006

Investigational Site Number : 2030004, Praha 5 - Motole

20089

Investigational Site Number : 3800001, Rozzano

20132

Investigational Site Number : 3800006, Milan

21100

Investigational Site Number : 3800005, Varese

23507

Eastern Virginia Medical School Site Number : 8400010, Norfolk

28040

Investigational Site Number : 7240004, Madrid / Madrid

28222

Investigational Site Number : 7240007, Majadahonda

30599

Investigational Site Number : 2030012, Pilsen

31000

Investigational Site Number : 4840002, Chihuahua City

31059

Investigational Site Number : 2500007, Toulouse

31080

Investigational Site Number : 7240006, Pamplona

33520

Investigational Site Number : 2460002, Tampere

33613

Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027, Tampa

34000

Investigational Site Number : 4840004, Durango

34295

Investigational Site Number : 2500005, Montpellier

40220

Advanced ENT and Allergy Site Number : 8400013, Louisville

40225

Investigational Site Number : 2760004, Düsseldorf

41009

Investigational Site Number : 7240001, Seville

43235

Optimed Research, LTD Site Number : 8400014, Columbus

44100

Investigational Site Number : 4840003, Guadalajara

44195

Cleveland Clinic Foundation Site Number : 8400029, Cleveland

48149

Investigational Site Number : 2760001, Münster

50005

Investigational Site Number : 2030001, Hradec Králové

50134

Investigational Site Number : 3800004, Florence

53203

Investigational Site Number : 2030002, Pardubice

59037

Investigational Site Number : 2500002, Lille

60611

Northwestern University Site Number : 8400001, Chicago

60612

University of Illinois, Chicago

63000

Investigational Site Number : 6160006, Środa Wielkopolska

65212

University of Missouri Health Care - University Hospital Site Number : 8400016, Columbia

70852

Investigational Site Number : 2030003, Ostrava - Poruba

73120

Allergy, Asthma and Clinical Research Center Site Number : 8400037, Oklahoma City

74137

Essential Medical Research, LLC Site Number : 8400024, Tulsa

77030

University of Texas Health Science Center- Site Number : 8400019, Houston

81377

Investigational Site Number : 2760003, München

84790

Chryaslis Clinical Research Site Number : 8400017, St. George

85925

Investigational Site Number : 2500006, La Roche-sur-Yon

90048

Cedars Sinai Medical Center Site Number : 8400026, Los Angeles

90141

Investigational Site Number : 6160007, Lodz

94010

Investigational Site Number : 2500009, Créteil

94275

Investigational Site Number : 2500008, Le Kremlin-Bicêtre

95123

Investigational Site Number : 3800003, Catania

97239

Oregon Health & Science University Site Number : 8400031, Portland

200222

Investigational Site Number : 6420004, Craiova

500283

Investigational Site Number : 6420002, Brasov

N6A 5A5

Investigational Site Number : 1240004, London

H4A 3J1

Investigational Site Number : 1240002, Montreal

G1V 4G5

Investigational Site Number : 1240003, Québec

256 01

Investigational Site Number : 2030007, Benešov

00029 HUS

Investigational Site Number : 2460003, Helsinki

00168

Investigational Site Number : 3800002, Rome

60-693

Investigational Site Number : 6160004, Poznan

04-141

Investigational Site Number : 6160008, Warsaw

40-611

Investigational Site Number : 6160005, Katowice

30-033

Investigational Site Number : 6160001, Krakow

2801-951

Investigational Site Number : 6200005, Almada

3814-501

Investigational Site Number : 6200003, Aveiro

4810-061

Investigational Site Number : 6200006, Guimarães

4454-509

Investigational Site Number : 6200001, Matosinhos Municipality

4520-211

Investigational Site Number : 6200007, Santa Maria da Feira

08036

Investigational Site Number : 7240005, Barcelona

08907

Investigational Site Number : 7240008, L'Hospitalet de Llobregat

413 45

Investigational Site Number : 7520003, Gothenburg

221 85

Investigational Site Number : 7520002, Lund

171 76

Investigational Site Number : 7520001, Stockholm

WN6 9EP

Investigational Site Number : 8260003, Wigan

M23 9LT

Investigational Site Number : 8260002, Manchester

NE7 7DN

Investigational Site Number : 8260001, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT04998604 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients | Biotech Hunter | Biotech Hunter